Trial Details

Not Recruiting
Basic Information
Clinical ID c5660
Identifier NL-OMON51097
Trial Title A Randomized, Placebo-controlled, Double-blind, Parallel-group, Exploratory, Phase 2 Study of the Efficacy and Safety of Oral AMT-101 in Combination with Adalimumab in Subjects with Moderate to Severe Ulcerative Colitis. - AMT-101-203
Trial URL Visit Original Page
Study Information
Study Results

NULL
Conditions Inflammatory Bowel Disease Ulcerative Colitis;10017969
Interventions Both groups are treated with adalimumab for 8 weeks, per standard dose as prescribed1 group takes 1 tablet of AMT-101 once a day. The other group takes 1 placebo tablet once a day
Participant Information
Sponsor Applied Molecular Tranport Inc.
City NULL
Country/Region Netherlands
Enrollment Criteria
Sex Requirement NOT SPECIFIED
Age Requirement ADULT, ELDER, OLDER_ADULT
Study Design
Study Type Interventional
Phase NULL
Time Information
Start Date NULL
Primary Completion Date NULL
Completion Date NULL